快要 飞的 《药股》 讨论区

雨若情

我看上一个电视机橱很美
自己掏腰包很心痛，如果有cvm赞助就不错下的说

~刹那恍惚~

现在敢敢入货, 别说电视机橱啦, 再加多一个Plasma 52inches 都可以......

kelvin234

没错,敢敢去买多点CVM吧,橱柜加沙发都买到

软趴趴

对BPAX有什么看法？？
刚收购了CEGE。

wobushi

原帖由 雨若情 于 29-10-2009 07:55 PM 发表
我尝试一下用赌鬼式回答你这个问题。
基本上这两个股票就像云顶两张赌桌
（不过是在外面普通会员赌的）
当然赌桌坏掉的机会很小（很小的机会公司破产）
可是你问大家，你几点要买庄还是贤
很难回答你吧。。 ...

第一次看到有人丢圣杯买股


CVM USD15K 变 10K, 我还是静静

现在是股市调整期 ，什么股票都下
耐心等等下

[ 本帖最后由 wobushi 于 30-10-2009 11:37 AM 编辑 ]

葉芬

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        9,873.00  4:47am ET        Down 30.00 (0.30%)

m.i.k.e

原帖由 wobushi 于 30-10-2009 11:34 AM 发表


第一次看到有人丢圣杯买股


CVM USD15K 变 10K, 我还是静静

现在是股市调整期 ，什么股票都下
耐心等等下

丢铜板来决定,我就试过.

葉芬

CEL-SCI Corp. (CVM) Support & Resistance Levels - 11/2/09

Resistance Levels - $1.20, $1.45, $1.60, $1.70

Support Levels - $1.00, $0.92, $0.80



CEL-SCI Corp. (CVM) closed back above $1.00 Friday after hitting a low of $0.92 on Thursday. I have been warning of this fall ever since CVM broke below $1.60 in early October. There are basically no fundamentals but a lot of third party websites promoting this stock in the form of press releases. As for the technicals, if CVM can close above $1.20, I will jump in for a quick trade.. CVM needs to get back above the 10 & 50 day moving averages for a recovery to happen.

葉芬

Discovery Laboratories Inc. (DSCO) Support & Resistance Levels - 11/2/09

Resistance Levels - $0.97, $1.00, $1.02. $1.05, $1.20

Support Levels - $0.85, $0.78, $0.65




Discovery Laboratories Inc. (DSCO) continues the oversold bounce which started two trading sessions ago. The stock will now be facing some major resistance located between $0.97 - $1.05. A close above $1.05 would be very bullish. Support is now located at $0.85, I would be a seller below $0.85.

葉芬

November 2nd CEOcast Weekly Newsletter
November 1, 2009 · Filed Under Stock Newsletters

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that it has received more than $10 million over the past 60 days from the exercise of warrants by investors to purchase the company’s common stock.  These additional funds increased the gross proceeds raised in the last 60 days to approximately $30 million, which the company has indicated that it expects to use towards its pivotal Phase III clinical trial with its cancer drug Multikine and to accelerate the development of its LEAPS compound for the treatment of H1N1 hospitalized patients.  Since the beginning of the year, the company has been able to strengthen its balance sheet significantly, raising gross proceeds in excess of $43 million and eliminating its Series K convertible notes which had an initial principal value of $8.3 million. Shares lost 26 cents on the week to close at $1.05.

m.i.k.e

lupus 患者的喜讯......

Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA™ in Systemic Lupus Erythematosus

http://www.businesswire.com/port ... 1005048&newsLang=en

http://www.nytimes.com/2009/11/03/business/03lupus.html?partner=yahoofinance

Human Genome Sciences said early Monday that its experimental drug to treat lupus was effective in its second big clinical trial, raising the chances that the first new treatment for the disease in more than 40 years will make it to market.

Doctors, lupus patients and Wall Street investors have had high hopes for the drug, called Benlysta, since it succeeded in its first clinical trial in July, to almost everyone’s surprise. Before that, several other drug candidates from numerous companies had failed in treating lupus.

But to win approval to market the drug from the Food and Drug Administration, Human Genome Sciences and its partner, GlaxoSmithKline, needed a second successful trial. Having achieved that with the results announced Monday, the companies said they would file for approval of the drug in both the United States and Europe in the first half of 2010.

“The lupus community has waited for decades for one positive phase three trial of an investigative drug developed for lupus,” Dr. Joan T. Merrill, a lupus expert at the Oklahoma Medical Research Foundation and an investigator in the trial, said in a statement issued by Human Genome Sciences and GlaxoSmithKline. “Now we have two.”

Still, the drug did not perform as well in the second trial as in the first. That might temper what was expected to be a big rise in Human Genome’s stock on Monday. The biotechnology company, based in Rockville, Md., does not yet have any drugs on the market.

One recent study estimated that 322,000 Americans definitely or probably have systemic lupus erythematosus, the most common form of the disease and the one against which Benlysta was tested. Many of the sufferers are women of child-bearing age.

Lupus is an autoimmune condition, in which the body’s defense system against pathogens attacks the body’s own tissue. It can cause rashes, arthritis, mouth sores, kidney damage and other problems.

But since the symptoms wax and wane and differ from one person to another, it has been difficult to demonstrate in a clinical trial that a drug is effective against it.

In the primary measure of the drug’s effectiveness, 43.2 percent of patients taking a high dose of Benlysta had a significant improvement in their symptoms after one year, as did 40.6 percent of those taking a lower dose of the drug. By contrast, only 33.8 percent of patients getting a placebo had such an improvement.

But the difference between the results for the drug and the placebo were statistically significant only for the higher dose. In the first trial, both doses provided statistically meaningful improvements.

There were some secondary measures for which the higher high dose did not differ from placebo in a statistically significant way in the second trial.

These included the assessment of the doctors as to how their patients were doing, an index measuring the patient’s quality of life, and the proportion of patients who were able to significantly reduce their use of steroids. Steroids, which suppress the immune system, are commonly used to treat lupus but they can have severe side effects.

One reason for the difference could be that the second trial, involving 819 patients, took place primarily in North America and Europe, while the first trial had taken place in Asia, South America and Eastern Europe. It is likely that the standard of medical care in the United States and Europe is higher than in those other regions, so patients getting the placebo did relatively better.

The companies said the rate of side effects were not very different between those getting Benlysta and those getting the placebo. However, three patients getting the drug died, while none getting the placebo did.

The shares of Human Genome Sciences, which traded at $3.32 the day before the positive first trial was announced in July, closed Friday at $18.69. Analysts estimate Benlysta could eventually have annual sales of a few billion dollars.

Glaxo, a large and diversified pharmaceutical company based in London, has less riding on this drug.

Benlysta, also known as belimumab, blocks a protein that stimulates B cells, which are part of the immune system. Human Genome, a pioneer in genomics, discovered the gene for that protein. That would make Benlysta, should it be approved, one of the first drugs to arise from genomics.

[ 本帖最后由 m.i.k.e 于 2-11-2009 03:16 PM 编辑 ]

葉芬

原帖由 m.i.k.e 于 2-11-2009 03:13 PM 发表
lupus 患者的喜讯......

Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA™ in Systemic Lupus Erythematosus

http://www.busin ...

恭喜。 HGSI股東。


DJ Future Pre-Market  還不错.

YMZ09.CBT

Mini Dow Jones Indus.-$5 Dec 09

9,703.00  3:08am ET

39.00 (0.40%)

m.i.k.e

原帖由 葉芬 于 2-11-2009 04:21 PM 发表



恭喜。 HGSI股東。


DJ Future Pre-Market  還不错.

YMZ09.CBTMini Dow Jones Indus.-$5 Dec 099,703.00  3:08am ET 39.00 (0.40%)

先别恭喜股东. 搞不好像 SPPI那样.....

葉芬

原帖由 m.i.k.e 于 2-11-2009 04:29 PM 发表


先别恭喜股东. 搞不好像 SPPI那样.....

不會吧。那有次次那樣幸運的

m.i.k.e

不懂 CARI 里有几个是 HGSI 的股东?

你有再买回吗?

葉芬

原帖由 m.i.k.e 于 2-11-2009 04:34 PM 发表
不懂 CARI 里有几个是 HGSI 的股东?

你有再买回吗?

沒有。

m.i.k.e

原帖由 葉芬 于 2-11-2009 04:35 PM 发表



沒有。

好可惜.......你错过了和我双飞双......的机会.

葉芬

原帖由 m.i.k.e 于 2-11-2009 04:55 PM 发表
好可惜.......你错过了和我双飞双......的机会.

m.i.k.e

来了!   来了 !



Human Genome Sciences, Inc. (HGSI) Pre-Market Trading

Human Genome Sciences, Inc.

Pre-Market Last:	$ 23	Pre-Market High:	$ 23
Pre-Market Volume:	6,100	Pre-Market Low:	$ 21.88

Pre-Market Time (ET)	Pre-Market Price	Pre-Market Share Volume
04:35	$ 23	400
04:34	$ 23	200
04:34	$ 23	400
04:19	$ 21.88	200
04:18	$ 21.88	1,000
04:17	$ 21.88	500
04:15	$ 21.88	400
04:15	$ 21.88	3,000

m.i.k.e

还要等一个小时.....煎熬啊.....

要办个可以 trade pre-market 的平台才行.

讲了整半年,都还没有去办 etrade 或 ameritrade.